Advanced Search

Project: Systematic Review of Calcineurin Inhibitors for Renal Transplant

Public Report Complete



Project Summary

Title and Description


Key Questions


Associated Extraction Forms

Title Created by Key Questions Addressed Form Notes
Therapeutic Monitoring Brian Leas 1
Cyclosporine Monitoring Timepoints Brian Leas 2
Comparative Effectiveness of Regimens Brian Leas 3


Associated Studies (each link opens a new tab)

Title Author Year
Clinical evaluation of the QMS® Tacrolimus immunoassay. Leung EK., Yi X., Gloria C., Yeo KT. 2014
Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. Shipkova M., Vogeser M., Ramos PA., Verstraete AG., Orth M., Schneider C., Wallemacq P. 2014
Cloned enzyme donor immunoassay tacrolimus assay compared with high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in liver and renal transplant recipients. Westley IS., Taylor PJ., Salm P., Morris RG. 2007
Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus. Borrows R., Chusney G., Loucaidou M., James A., Stichbury J., Van Tromp J., Cairns T., Griffith M., Hakim N., McLean A., Palmer A., Papalois V., Taube D. 2006
Comparison of an ELISA and an LC/MS/MS method for measuring tacrolimus concentrations and making dosage decisions in transplant recipients. Staatz CE., Taylor PJ., Tett SE. 2002
High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants. Salm P., Taylor PJ., Clark A., Balderson GA., Grygotis A., Norris RL., Lynch SV., Shaw LM., Pond SM. 1997
Reduced exposure to calcineurin inhibitors in renal transplantation. Ekberg H., Tedesco-Silva H., Demirbas A., Vítko S., Nashan B., Gürkan A., Margreiter R., Hugo C., Grinyó JM., Frei U., Vanrenterghem Y., Daloze P., Halloran PF. 2007
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Holdaas H., Rostaing L., Serón D., Cole E., Chapman J., Fellstrøm B., Strom EH., Jardine A., Midtvedt K., Machein U., Ulbricht B., Karpov A., O'Connell PJ. 2011
A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Chadban SJ., Eris JM., Kanellis J., Pilmore H., Lee PC., Lim SK., Woodcock C., Kurstjens N., Russ G. 2014
Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Ekberg H., Grinyó J., Nashan B., Vanrenterghem Y., Vincenti F., Voulgari A., Truman M., Nasmyth-Miller C., Rashford M. 2007
Randomized trial of Alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Vathsala A., Ona ET., Tan SY., Suresh S., Lou HX., Casasola CB., Wong HC., Machin D., Chiang GS., Danguilan RA., Calne R. 2005
Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Gaston RS., Kaplan B., Shah T., Cibrik D., Shaw LM., Angelis M., Mulgaonkar S., Meier-Kriesche HU., Patel D., Bloom RD. 2009
Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine. Spagnoletti G., Citterio F., Favi E., Rossi E., Delreno F., De Santis I., Salerno MP., Gargiulo A., Castagneto M. 2009
Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Hernández D., Miquel R., Porrini E., Fernández A., González-Posada JM., Hortal L., Checa MD., Rodríguez A., García JJ., Rufino M., Torres A. 2007
Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy. Tang SC., Chan KW., Tang CS., Lam MF., Leung CY., Tse KC., Li CS., Ho YW., Tong MK., Lai KN., Chan TM. 2006
A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients. Cai L., Zeng F., Liu B., Wei L., Chen Z., Jiang J. 2014
Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients. Chadban S., Eris J., Russ G., Campbell S., Chapman J., Pussell B., Trevillian P., Ierino F., Thomson N., Hutchison B., Irish A., Woodcock C., Kurstjens N., Walker R. 2013
A 50% reduction in cyclosporine exposure in stable renal transplant recipients: renal function benefits. Etienne I., Toupance O., Bénichou J., Thierry A., Al Najjar A., Hurault de Ligny B., Le Meur Y., Westeel PF., Marquet P., François A., Hellot MF., Godin M. 2010
Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. Fangmann J., Arns W., Marti HP., Hauss J., Ketteler M., Beckurts T., Boesmueller C., Pohanka E., Martin PY., Gerhardt M., Farese S., Neumayer HH., Floege J., Gurr C., Budde K. 2010
Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. Budde K., Bosmans JL., Sennesael J., Zeier M., Pisarski P., Schütz M., Fischer W., Neumayer HH., Glander P. 2007
Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. Cibrik D., Meier-Kriesche HU., Bresnahan B., Wu YM., Klintmalm G., Kew CE., Kuo PC., Whelchel J., Cohen D., Baliga P., Akalin E., Benedetti E., Wright F., Lieberman B., Ulbricht B., Jensik S. -- Not Found --
Low-dose versus high-dose cyclosporine induction protocols in renal transplantation. Ghafari A., Makhdoomi K., Ahmadpour P., Afshari AT., Fallah MM., Rad PS. 2007
Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The 'reference' study. Frimat L., Cassuto-Viguier E., Charpentier B., Noël C., Provôt F., Rostaing L., Glotz D., Sraer JD., Bourbigot B., Moulin B., Lang P., Ducloux D., Pouteil-Noble C., Girardot-Seguin S., Kessler M. 2006
Long-Term Impact of Cyclosporin Reduction with MMF Treatment in Chronic Allograft Dysfunction: REFERENECE Study 3-Year Follow Up. Frimat L., Cassuto-Viguier E., Provôt F., Rostaing L., Charpentier B., Akposso K., Moal MC., Lang P., Glotz D., Caillard S., Ducloux D., Pouteil-Noble C., Girardot-Seguin S., Kessler M. 2010
A randomized controlled trial of immunosuppression conversion for the treatment of chronic allograft nephropathy. Stoves J., Newstead CG., Baczkowski AJ., Owens G., Paraoan M., Hammad AQ. 2004
A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Pascual M., Curtis J., Delmonico FL., Farrell ML., Williams WW., Kalil R., Jones P., Cosimi AB., Tolkoff-Rubin N. 2003
A controlled trial comparing two doses of cyclosporine in conjunction with mycophenolate mofetil and corticosteroids. de Sévaux RG., Gregoor PJ., Hené RJ., Hoitsma AJ., Vos P., Weimar W., Van Gelder T., Hilbrands LB. 2001
Renal Function and NODM in De Novo Renal Transplant Recipients Treated with Standard and Reduced Levels of Tacrolimus in Combination with EC-MPS. Chan L., Andres A., Bunnapradist S., Gugliuzza K., Parasuraman R., Peddi VR., Cassuto E., Hart M. 2012
A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. Kamar N., Rostaing L., Cassuto E., Villemain F., Moal MC., Ladrière M., Barrou B., Ducloux D., Chaouche K., Quéré S., Di Giambattista F., Be F. 2012
Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results. Bolin P., Shihab FS., Mulloy L., Henning AK., Gao J., Bartucci M., Holman J., First MR. 2008
The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study. Mühlbacher F., Neumayer HH., del Castillo D., Stefoni S., Zygmunt AJ., Budde K. 2014
Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Cibrik D., Silva HT., Vathsala A., Lackova E., Cornu-Artis C., Walker RG., Wang Z., Zibari GB., Shihab F., Kim YS. 2013
Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results. Takahashi K., Uchida K., Yoshimura N., Takahara S., Teraoka S., Teshima R., Cornu-Artis C., Kobayashi E. 2013
Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients. Oh CK., Huh KH., Ha J., Kim YH., Kim YL., Kim YS. 2015
Effect of everolimus on left ventricular hypertrophy of de novo kidney transplant recipients: a 1 year, randomized, controlled trial. Paoletti E., Marsano L., Bellino D., Cassottana P., Cannella G. 2012
Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients. Bertoni E., Larti A., Rosso G., Zanazzi M., Di Maria L., Salvadori M. -- Not Found --
Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Salvadori M., Scolari MP., Bertoni E., Citterio F., Rigotti P., Cossu M., Dal Canton A., Tisone G., Albertazzi A., Pisani F., Gubbiotti G., Piredda G., Busnach G., Sparacino V., Goepel V., Messa P., Berloco P., Montanaro D., Veroux P., Federico S., Bartezaghi M., Corbetta G., Ponticelli C. 2009
Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Nashan B., Curtis J., Ponticelli C., Mourad G., Jaffe J., Haas T. 2004
A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. Bechstein WO., Paczek L., Wramner L., Squifflet JP., Zygmunt AJ. -- Not Found --
Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Langer RM., Hené R., Vitko S., Christiaans M., Tedesco-Silva H., Ciechanowski K., Cassuto E., Rostaing L., Vilatoba M., Machein U., Ulbricht B., Junge G., Dong G., Pascual J. 2012
Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Chan L., Greenstein S., Hardy MA., Hartmann E., Bunnapradist S., Cibrik D., Shaw LM., Munir L., Ulbricht B., Cooper M. 2008
Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. Lo A., Egidi MF., Gaber LW., Shokouh-Amiri MH., Nazakatgoo N., Fisher JS., Gaber AO. 2004
Deferred pre-emptive switch from calcineurin inhibitor to sirolimus leads to improvement in GFR and expansion of T regulatory cell population: a randomized, controlled trial. Bansal D., Yadav AK., Kumar V., Minz M., Sakhuja V., Jha V. 2013
Conversion from cyclosporine to everolimus at 4.5 months posttransplant: 3-year results from the randomized ZEUS study. Budde K., Lehner F., Sommerer C., Arns W., Reinke P., Eisenberger U., Wüthrich RP., Scheidl S., May C., Paulus EM., Mühlfeld A., Wolters HH., Pressmar K., Stahl R., Witzke O. 2012
A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Watson CJ., Firth J., Williams PF., Bradley JR., Pritchard N., Chaudhry A., Smith JC., Palmer CR., Bradley JA. 2005
Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Budde K., Rath T., Sommerer C., Haller H., Reinke P., Witzke O., Suwelack B., Baeumer D., May C., Porstner M., Arns W. 2015
Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Weir MR., Mulgaonkar S., Chan L., Shidban H., Waid TH., Preston D., Kalil RN., Pearson TC. 2011
Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Schena FP., Pascoe MD., Alberu J., del Carmen Rial M., Oberbauer R., Brennan DC., Campistol JM., Racusen L., Polinsky MS., Goldberg-Alberts R., Li H., Scarola J., Neylan JF. 2009
Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen. Chhabra D., Alvarado A., Dalal P., Leventhal J., Wang C., Sustento-Reodica N., Najafian N., Skaro A., Levitsky J., Mas V., Gallon L. 2013
Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. Silva HT., Felipe CR., Garcia VD., Neto ED., Filho MA., Contieri FL., de Carvalho DD., Pestana JO. 2013
Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Heilman RL., Younan K., Wadei HM., Mai ML., Reddy KS., Chakkera HA., Gonwa TA. 2011
Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA. Rostaing L., Hertig A., Albano L., Anglicheau D., Durrbach A., Vuiblet V., Moulin B., Merville P., Hazzan M., Lang P., Touchard G., Hurault deLigny B., Quéré S., Di Giambattista F., Dubois YC., Rondeau E. 2015
Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Mjörnstedt L., Sørensen SS., von Zur Mühlen B., Jespersen B., Hansen JM., Bistrup C., Andersson H., Gustafsson B., Undset LH., Fagertun H., Solbu D., Holdaas H. 2012
Sirolimus versus calcineurin inhibitor-based immunosuppressive therapy in kidney transplantation: a 4-year follow-up. Nafar M., Alipour B., Ahmadpoor P., Pour-Reza-Gholi F., Samadian F., Samavat S., Farhangi S. 2012
Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Guba M., Pratschke J., Hugo C., Krämer BK., Nohr-Westphal C., Brockmann J., Andrassy J., Reinke P., Pressmar K., Hakenberg O., Fischereder M., Pascher A., Illner WD., Banas B., Jauch KW. 2010
Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Lebranchu Y., Thierry A., Toupance O., Westeel PF., Etienne I., Thervet E., Moulin B., Frouget T., Le Meur Y., Glotz D., Heng AE., Onno C., Buchler M., Girardot-Seguin S., Hurault de Ligny B. 2009
Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Durrbach A., Rostaing L., Tricot L., Ouali N., Wolf P., Pouteil-Noble C., Kessler M., Viron B., Thervet E. 2008
The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes. Barsoum RS., Morsey AA., Iskander IR., Morgan MM., Fayad TM., Atalla NT., Wafik H., Grace RA., Adel N., Khalil SS. 2007
Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Bakker RC., Hollander AA., Mallat MJ., Bruijn JA., Paul LC., de Fijter JW. 2003
Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. MacPhee IA., Bradley JA., Briggs JD., Junor BJ., MacPherson SG., McMillan MA., Rodger RS., Watson MA. 1998
The effect of immunosuppressive drugs on quality of life after renal transplantation. Hilbrands LB., Hoitsma AJ., Koene RA. 1995
Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Dudley C., Pohanka E., Riad H., Dedochova J., Wijngaard P., Sutter C., Silva HT. 2005
Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Rostaing L., Massari P., Garcia VD., Mancilla-Urrea E., Nainan G., del Carmen Rial M., Steinberg S., Vincenti F., Shi R., Di Russo G., Thomas D., Grinyó J. 2011
Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Pascual J., Bloom D., Torrealba J., Brahmbhatt R., Chang Z., Sollinger HW., Knechtle SJ. 2008
Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Hazzan M., Buob D., Labalette M., Provot F., Glowacki F., Hoffmann M., Copin MC., Noel C. 2006
Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Stallone G., Di Paolo S., Schena A., Infante B., Grandaliano G., Battaglia M., Gesualdo L., Schena FP. 2003
Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. Schnuelle P., van der Heide JH., Tegzess A., Verburgh CA., Paul LC., van der Woude FJ., de Fijter JW. 2002
Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal. Mourer JS., Hartigh Jd., van Zwet EW., Mallat MJ., Dubbeld J., de Fijter JW. 2012
Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Suwelack B., Gerhardt U., Hohage H. 2004
Long-term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation - results from an aborted trial. Åsberg A., Apeland T., Reisaeter AV., Foss A., Leivestad T., Heldal K., Thorud LO., Eriksen BO., Hartmann A. -- Not Found --
Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Abramowicz D., Manas D., Lao M., Vanrenterghem Y., Del Castillo D., Wijngaard P., Fung S. 2002
Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. Smak Gregoor PJ., de Sévaux RG., Ligtenberg G., Hoitsma AJ., Hené RJ., Weimar W., Hilbrands LB., van Gelder T. 2002
Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Gonwa TA., Hricik DE., Brinker K., Grinyo JM., Schena FP. 2002
Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Johnson RW., Kreis H., Oberbauer R., Brattström C., Claesson K., Eris J. 2001
The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients. Flechner SM., Glyda M., Cockfield S., Grinyó J., Legendre Ch., Russ G., Steinberg S., Wissing KM., Tai SS. 2011
Steroid or tacrolimus withdrawal in renal transplant recipients using sirolimus. de Sandes Freitas TV., Harada KM., Felipe CR., Galante NZ., Sampaio EL., Ikehara E., Alfieri F., Tedesco-Silva Júnior H., Medina-Pestana JO. 2011
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Vincenti F., Charpentier B., Vanrenterghem Y., Rostaing L., Bresnahan B., Darji P., Massari P., Mondragon-Ramirez GA., Agarwal M., Di Russo G., Lin CS., Garg P., Larsen CP. 2010
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Durrbach A., Pestana JM., Pearson T., Vincenti F., Garcia VD., Campistol J., Rial Mdel C., Florman S., Block A., Di Russo G., Xing J., Garg P., Grinyó J. 2010
Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Flechner SM., Goldfarb D., Modlin C., Feng J., Krishnamurthi V., Mastroianni B., Savas K., Cook DJ., Novick AC. 2002
A Prospective Randomised Paired Trial of Sirolimus versus Tacrolimus as Primary Immunosuppression following Non-Heart Beating Donor Kidney Transplantation. Asher J., Vasdev N., Wyrley-Birch H., Wilson C., Soomro N., Rix D., Jaques B., Manas D., Torpey N., Talbot D. 2014
Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Glotz D., Charpentier B., Abramovicz D., Lang P., Rostaing L., Rifle G., Vanrenterghem Y., Berthoux F., Bourbigot B., Delahousse M., Chalopin JM., Cassuto E., Lefrançois N. 2010
Short-term results under three different immunosuppressive regimens at one center. Schaefer HM., Kizilisik AT., Feurer I., Nylander WA., Langone AJ., Helderman JH., Shaffer D. 2006
Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Groth CG., Bäckman L., Morales JM., Calne R., Kreis H., Lang P., Touraine JL., Claesson K., Campistol JM., Durand D., Wramner L., Brattström C., Charpentier B. 1999
Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant. Refaie AF., Mahmoud KM., Ismail AM., Sheashaa HA., Kamal AI., Ghoneim MA. 2011
Conversion from cyclosporine to sirolimus in chronic renal allograft dysfunction: a 4-year prospective study. Han F., Wu J., Huang H., Zhang X., He Q., Wang Y., Wang S., Wang H., Chen J. 2011
Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy. Liu M., Zhang W., Gu M., Yin C., Zhang WY., Lv Q., Xu D. 2007
Conversion to low-dose tacrolimus or rapamycin 3 months after kidney transplantation: a prospective, protocol biopsy-guided study. Pankewycz O., Leca N., Kohli R., Weber-Shrikant E., Said M., Alnimri M., Feng L., Patel S., Laftavi MR. 2011
Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. Cataneo-Dávila A., Zúñiga-Varga J., Correa-Rotter R., Alberú J. 2009
Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. Stallone G., Infante B., Schena A., Battaglia M., Ditonno P., Loverre A., Gesualdo L., Schena FP., Grandaliano G. 2005
High incidence of rejection episodes and poor tolerance of sirolimus in a protocol with early steroid withdrawal and calcineurin inhibitor-free maintenance therapy in renal transplantation: experiences of a randomized prospective single-center study. Burkhalter F., Oettl T., Descoeudres B., Bachmann A., Guerke L., Mihatsch MJ., Dickenmann M., Steiger J. 2012
Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant. Rivelli RF., Gonçalves RT., Leite M., Santos MA., Delgado AG., Cardoso LR., Takiya CM. 2015
Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation. Hamdy AF., El-Agroudy AE., Bakr MA., Mostafa A., El-Baz M., El-Shahawy el-M., Ghoneim MA. 2005
Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Lo A., Egidi MF., Gaber LW., Amiri HS., Vera S., Nezakatgoo N., Gaber AO. 2004
Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. Hazzan M., Labalette M., Copin MC., Glowacki F., Provôt F., Pruv FR., Noël C. 2005
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Budde K., Becker T., Arns W., Sommerer C., Reinke P., Eisenberger U., Kramer S., Fischer W., Gschaidmeier H., Pietruck F. 2011
Application of low-dose calcineurin inhibitors in living-related donor renal transplantation Xu DL, Bai JM, Yu X, et al 2011
Measurement of whole blood tacrolimus level by high performance liquid chromatography tandem mass spectrometry in renal transplant recipients - a single center perspective Chan YH, Ho CS, Shek CC, et al 2005
Conversion of C-0 to C-2 monitoring of cyclosporine in stable kidney transplant patients. Jirasiritham S., Mavichak V., Danviriyasup K., Jirasiritham S. 2003
Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study. Kyllönen LE., Salmela KT. 2006
Long-term comparative results of C0 and C2 monitoring of CyA in renal transplanted patients. Paydaş S., Balal M., Sertdemir Y., Seyrek N., Karayaylali I. 2005
Outcome of microemulsion cyclosporine C2 concentration monitoring in kidney transplantation. Praditpornsilpa K., Avihingsanon Y., Nivatvong S., Kansanabuch T., Eiam-Ong S., Tiranathanagul K., Chusil S., Tungsanga K. 2005
Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-center experience. Bîrsan T., Loinig C., Bodingbauer M., Wekerle T., Rockenschaub S., Berlakovich G., Soliman T., Mühlbacher F., Steininger R. 2004
Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Giese T., Zeier M., Meuer S. 2004
Analytical performance of the CEDIA cyclosporine PLUS whole blood immunoassay. Butch AW., Fukuchi AM. 2004
Evaluation of four automated methods for determination of whole blood cyclosporine concentrations. Hamwi A., Veitl M., Männer G., Ruzicka K., Schweiger C., Szekeres T. 1999
Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. Schütz E., Svinarov D., Shipkova M., Niedmann PD., Armstrong VW., Wieland E., Oellerich M. 1998
A method of relating whole blood cyclosporin A results by HPLC to Abbott TDx monoclonal and polyclonal immunoassays. Roberts NB., Dutton J., Tewari A., Bone MJ., Sells RA., Ward RG., West CR. 1995




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/